Designation of Isavuconazonium Sulfate as an orphan drug by JACE Pharma

Overview

The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to provide for the regulation of therapeutic goods, including medicines, medical devices, and blood and tissues. One of the aims of this legislation is to ensure the safety, quality, and efficacy of therapeutic goods available in Australia. The Act was introduced to address the need for a comprehensive regulatory framework that would protect public health by controlling the importation, supply, and advertising of therapeutic goods. The 2016 designation of Isavuconazonium sulfate as an orphan drug under the Therapeutic Goods Act 1989 by Dr Anthony Gill, the Delegate of the Secretary, was made to encourage the development and availability of treatments for rare diseases. Isavuconazonium sulfate, developed by JACE Pharma Pty Ltd, was designated for the treatment of invasive aspergillosis and invasive mucormycosis in patients 18 years of age and older. This designation recognises the need for specialised treatments for rare and life-threatening conditions, while also supporting the pharmaceutical industry in the development of such therapies.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) within the Department of Health, provides the legislative framework for the regulation of therapeutic goods in Australia. The Act applies to therapeutic goods, which include medicines, medical devices, blood and blood components, tissues, and combinations of these products. The scope of this particular legislative instrument, Gazette C2016G00046, extends to the designation of Isavuconazonium sulfate as an orphan drug for the treatment of specific life-threatening fungal infections, invasive aspergillosis and invasive mucormycosis, in patients aged 18 years and older. This designation is aimed at encouraging the research and development of treatments for rare diseases by providing certain incentives and regulatory benefits. The instrument is applicable nationally across the Commonwealth of Australia, and it is effective from 17 December 2015, the date of signing by Dr Anthony Gill, the Delegate of the Secretary. The sponsor of Isavuconazonium sulfate, JACE Pharma Pty Ltd, is subject to the obligations and benefits provided under this designation. This designation can be extended or further specified through subordinate instruments under the Therapeutic Goods Regulations 1990.

Key Provisions

The main operative section of this legislation is the designation of Isavuconazonium sulfate as an orphan drug under section 16J of the Therapeutic Goods Regulations 1990 (subsections 16J(2)). This means that the drug has been specifically identified for its therapeutic benefits in treating rare medical conditions, in this case, invasive aspergillosis and invasive mucormycosis in patients aged 18 and older. The forms of the drug that are approved for these indications are powder for injection and hard capsules. The sponsor for Isavuconazonium sulfate, responsible for ensuring compliance and quality, is JACE Pharma Pty Ltd. The obligations and requirements imposed by this designation are primarily on the sponsor, JACE Pharma Pty Ltd, and the Therapeutic Goods Administration (TGA). The sponsor must ensure that the drug meets the necessary quality, safety, and efficacy standards for its specified indications. This includes submitting relevant data and undergoing any required testing and evaluation by the TGA. The TGA, in turn, is responsible for overseeing the sponsor’s compliance and ensuring that the drug is appropriately designated as an orphan drug. This involves reviewing the submitted data and determining whether the drug indeed meets the criteria for orphan drug status, which typically includes the rarity of the condition it treats and the lack of alternative treatments. Failure to comply with the obligations and requirements set out by the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can lead to various consequences. If the sponsor, JACE Pharma Pty Ltd, fails to meet the necessary standards or provide the required information, the TGA can take action. This could include issuing infringement notices, which carry fines of up to $22,200 for a corporation for each day of the infringement, or legal action that can result in more substantial penalties. Additionally, the TGA can suspend or cancel the therapeutic goods registration, preventing the sale or supply of the drug in Australia. These measures ensure that only drugs that meet the required standards are available for use in the treatment of rare conditions.